Regulation of Self-Care Products in Canada

POLICY TYPE: Response to consultation

DATE: 2016-10-31

TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
        Health care and patient safety

Documents

CMA Response:
Regulation of Self-Care Products in Canada
Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada
https://policybase.cma.ca/link/policy13936

POLICY TYPE: Parliamentary submission
DATE: 2016-10-18
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
Health care and patient safety

Documents
Legalization, regulation and restriction of access to marijuana

https://policybase.cma.ca/link/policy11954

POLICY TYPE
Response to consultation

DATE
2016-08-29

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE  Response to consultation
DATE  2016-08-12
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

August 12, 2016

dr. [Name]

Director, Market Access Division
Canadian Medical Association

Dear Dr. [Name],

We are writing to provide our comments on Health Canada’s Consultation on “Plain and Standardized Packaging.”

We fully support the objective of making it easier for patients to identify their medications. As such, we are pleased to see Health Canada’s initiative. However, we would like to provide some additional comments:

1. **Impact on Patient Safety:**
   - While plain packaging has the potential to reduce confusion, it is important to ensure that patients can still identify their medications easily. Transparency and other features can be used to enhance patient safety.

2. **Regulatory Framework:**
   - The current regulatory framework needs to be clear and consistent across provinces. It is important to consider the implications of provincial differences on a national standard.

3. **Cost Considerations:**
   - We understand the cost implications of plain packaging. There is a need for a cost-benefit analysis to ensure that the benefits outweigh the costs.

4. **Consultation Process:**
   - The consultation process should be inclusive and collaborative. We encourage Health Canada to engage with various stakeholders, including patients, healthcare providers, and industry, to ensure a comprehensive approach.

We look forward to discussing these points further.

Sincerely,

[Name]

Canadian Medical Association

---

Note: The provided text is a sample and does not necessarily reflect the actual content of the document.
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

POLICY TYPE
Response to consultation

DATE
2016-01-20

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents